ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1609

Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1163

Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1605

Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1166

Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1444

Characterization and Comparison of MRI Findings in Axial Spondyloarthritis, Axial Psoriatic and Chronic Non-inflammatory Back Pain

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1585

Characterization of the Fecal Metabolome in Early Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0962

Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1212

Childhood Maltreatment Increases Risk of Chronic Widespread Pain: Counterfactual Analysis of UK Biobank

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1092

Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1040

Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 0999

Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1508

Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0908

Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1151

Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].